Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. PP2A activity restricts KRAS-mutant lung cancer cell line proliferative potential.
  • Fig. S2. MEKi resistance in KRAS-mutant lung cancer cells by PP2A inhibition.
  • Fig. S3. PPP2R1A inhibition drives MEKi resistance by increased AKT/mTOR pathway activities.
  • Fig. S4. Validation of PP2A inhibition as a druggable MEKi resistance mechanism in vivo.
  • Fig. S5. Analysis of xenograft tissues with respect to proliferation, apoptosis, and MYC protein expression.
  • Fig. S6. Pharmacological PP2A activation does not induce weight loss in animals.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1 (Microsoft Excel format). A549 cell DSRT.
  • Table S2 (Microsoft Excel format). Validation drug screen in NCI-H460 and NCI-H2122 cells.
  • Table S3 (Microsoft Excel format). Oligonucleotide sequences and antibody information.

[Download Tables S1 to S3]